Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 2
1967 4
1968 6
1969 3
1970 3
1971 7
1972 8
1973 6
1974 22
1975 16
1976 12
1977 9
1978 18
1979 12
1980 6
1981 8
1982 9
1983 9
1984 14
1985 18
1986 20
1987 19
1988 12
1989 14
1990 24
1991 24
1992 22
1993 30
1994 37
1995 28
1996 39
1997 25
1998 34
1999 42
2000 30
2001 36
2002 24
2003 25
2004 38
2005 23
2006 32
2007 31
2008 25
2009 36
2010 30
2011 34
2012 27
2013 24
2014 35
2015 36
2016 30
2017 28
2018 25
2019 31
2020 49
2021 49
2022 16
2023 9
2024 56

Search Results

1,290 results

Results by year

Filters applied: . Clear all
Page 1
The immunology of renal cell carcinoma.
Díaz-Montero CM, Rini BI, Finke JH. Díaz-Montero CM, et al. Nat Rev Nephrol. 2020 Dec;16(12):721-735. doi: 10.1038/s41581-020-0316-3. Epub 2020 Jul 30. Nat Rev Nephrol. 2020. PMID: 32733094 Review.
An Immune Atlas of Clear Cell Renal Cell Carcinoma.
Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B. Chevrier S, et al. Cell. 2017 May 4;169(4):736-749.e18. doi: 10.1016/j.cell.2017.04.016. Cell. 2017. PMID: 28475899 Free PMC article.
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. Pal SK, et al. Cancer Discov. 2024 Jul 1;14(7):1176-1189. doi: 10.1158/2159-8290.CD-24-0102. Cancer Discov. 2024. PMID: 38583184 Free PMC article. Clinical Trial.
Current Immunotherapies for Renal Cell Carcinoma.
Al-Marrawi MY, Holder SL. Al-Marrawi MY, et al. Curr Mol Pharmacol. 2016;9(3):252-263. doi: 10.2174/1874467208666150716121116. Curr Mol Pharmacol. 2016. PMID: 26177641 Review.
The tumor microenvironment in renal cell cancer.
Mier JW. Mier JW. Curr Opin Oncol. 2019 May;31(3):194-199. doi: 10.1097/CCO.0000000000000512. Curr Opin Oncol. 2019. PMID: 30985497 Free PMC article. Review.
Immunotherapy of kidney cancer.
Grivas PD, Redman BG. Grivas PD, et al. Curr Clin Pharmacol. 2011 Aug;6(3):151-63. doi: 10.2174/157488411797189406. Curr Clin Pharmacol. 2011. PMID: 21827390 Review.
Heavy Metal Enlightens Tumor Immunity.
Chen JH, Pelka K, Hacohen N. Chen JH, et al. Cell. 2017 May 4;169(4):567-569. doi: 10.1016/j.cell.2017.04.017. Cell. 2017. PMID: 28475889 Free PMC article.
Immunotherapy: Controlled attack.
Schmidt C. Schmidt C. Nature. 2016 Sep 15;537(7620):S109-10. doi: 10.1038/537S109a. Nature. 2016. PMID: 27626780 No abstract available.
Prognostic factors for metastatic kidney cancer.
Drucker BJ, Mazumdar M, Motzer RJ. Drucker BJ, et al. Cancer Treat Res. 2003;116:139-53. doi: 10.1007/978-1-4615-0451-1_8. Cancer Treat Res. 2003. PMID: 14650830 Review. No abstract available.
1,290 results